Olvimulogene nanivacirepvec

纳欧莫洛基

Report date: 2023/11/28 10:16:08

Base Information

Drug NameOlvimulogene nanivacirepvec
Drug Alias NameOlvi-VecOncolytic Vaccinia (Genelux)GL-ONC1GLV-1h68
ClassificationBiologics > Oncolytic virusVaccines > Application > Therapeutic vaccine
Mechanisms of ActionImmunomodulators
TargetsNot applicable
Therapy Area/IndicationsSolid tumoursFallopian Tube NeoplasmsSmall Cell Lung Carcinoma +[9] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited StatesGermanyUnited Kingdom +[4] 
CombinationsNo
Global Highest StatusPhase 3 Clinical
Highest Status in ChinaPhase 2 Clinical
Originator CompaniesGenelux
China Registration ClassN/A

Develop Information

Active CompaniesGenelux CorporationV2ACT Therapeutics LLCGenelux Corp +[4] 
Inactive CompaniesGenelux Gmbh
Active IndicationsFallopian Tube NeoplasmsSmall Cell Lung CarcinomaCarcinoma, Non-Small-Cell Lung +[7] 
Inactive IndicationsSolid tumoursHead and Neck Neoplasms

Other Information

ATC CodeN/A
Related LinksWikipedia